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Abstract 
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3.  
 
Experimental design: mCRC patients with KRAS ex2 wild-type received duligotuzumab or 
cetuximab and FOLFIRI until progression or intolerable toxicity. Mandatory tumor samples 
underwent mutation and biomarker analysis. Efficacy analysis was conducted in patients with 
RAS exon 2/3 wild-type tumors. 
 
Results: Of 134 randomized patients, 98 were RAS ex2/3 wild-type. Duligotuzumab provided 
no PFS or OR benefit compared to cetuximab; though there was a trend for lower ORR in the 
duligotuzumab arm. No relationship was seen between PFS or ORR and ERBB3, NRG1, or 
AREG expression. There were fewer skin rash events for duligotuzumab but more diarrhea. 
Although the incidence of grade ≥ 3 AEs was similar, the frequency of serious AEs was higher 
for duligotuzumab.  
 
Conclusions: Duligotuzumab plus FOLFIRI did not appear to improve the outcomes in patients 
with RAS exon 2/3 wild-type mCRC compared to cetuximab + FOLFIRI. 
 
 
Statement of translational relevance  
Duligotuzumab, a dual-action antibody to EGFR and HER3, shows preclinical efficacy in EGFR-
dependent CRC cell lines refractory to EGFR inhibition. We evaluated duligotuzumab compared 
to cetuximab in combination with FOLFIRI as second-line therapy in patients with RAS exon 2/3 
wild-type metastatic CRC and found no advantage to duligotuzumab. 
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Introduction 
 EGFR is a growth factor receptor with tyrosine kinase activity implicated in both 
colorectal (CRC) tumorigenesis and tumor progression, and its overexpression (found in 65%-
70% of human CRC) has been associated with advanced disease (1). Anti-EGFR monoclonal 
antibodies (mAbs) are established in the treatment of metastatic CRC (mCRC), either as single 
agent or in combination with chemotherapy (2-4). While the benefit was initially thought to be 
restricted to patients lacking hot spot mutations in KRAS exon 2, codons 12 and 13, a more 
recent retrospective analysis of Phase III studies with anti-EGFR mAbs either in first or second 
line mCRC identified additional mutations in KRAS or NRAS exons 2, 3, 4 as negative predictive 
biomarkers for EGFR inhibition (5-9). Consequently, the ESMO clinical practice guidelines for 
the treatment of mCRC were updated to recommend additional testing for KRAS mutations in 
exons 3 and 4, and NRAS mutations in exons 2-4 as a prerequisite for anti-EGFR antibody 
therapy (10). Similarly, NCCN guidelines now recommend against treating patients with known 
KRAS (exon 2 or non-exon 2) or NRAS mutation with either cetuximab or panitumumab (11). 
 Nonclinical and preliminary clinical data suggest a role for HER3 in acquired resistance 
to EGFR inhibitors (12-14). Yonesaka and coworkers (15) reported amplification of the HER2 
gene and/or increased concentrations of neuregulin (NRG1) the ligand for HER3 in cetuximab-
resistant clones of colorectal and lung cancers. Further analysis suggested that aberrant HER2 
signaling, through either HER2/HER2 dimers associated with gene amplification or HER2/HER3 
dimer activation through autocrine expression of neuregulin led to persistent ERK signaling and 
consequently to cetuximab resistance. Interestingly, a retrospective review of data from mCRC 
patients treated with cetuximab as a single agent or in combination with irinotecan (also 
reported in 15) found that those patients with a partial response had significantly lower baseline 
expression of NRG1 in plasma or tumor samples than patients with a best response of stable or 
progressive disease. Furthermore, patients with lower baseline plasma NRG1 levels had 
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significantly longer progression-free (PFS) and overall survival (OS) when compared with those 
with higher levels. 
 Clinical trial reports on the evaluation of therapeutics that inhibit HER3 dependent 
signaling are relatively rare, as are HER3-related biomarker studies that aim to identify clinically 
meaningful patient subsets. This is in part due to the attenuated enzymatic activity of HER3 that 
renders HER3 activity dependent on critical protein-protein interactions. Innovative methods for 
inhibiting activity often focus on these interactions and moreover, biomarkers of HER3 activity 
often include these interaction partners independent of HER3 expression. HER3 activity can be 
enhanced by elevated ligand or heterodimer expression or in some cases, activity is driven by 
multiple binding sites for signalling partners (i.e., PI3K). In addition, there is evidence for 
controlled HER3 feedback HER3 including altered transcription of HER3 itself. This was most 
clearly shown in a randomized Phase II trial of pertuzumab (a monoclonal antibody that targets 
HER2 and therefore inhibits heterodimerization of HER2 and HER3) in patients with platinum 
refractory ovarian cancer, those patients with low expression of HER3 in tumors (measured by 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) had a statistically 
significant improvement in PFS and numerically improved response rate and OS (16). These 
results, together with preclinical observations that activation of the HER2/HER3 signaling 
pathway by ligand stimulation leads to down regulation of HER3 through negative feedback 
modulation (17), as well the cumulative mechanisms of HER3 activation independent of 
enhance HER3 expression may suggest that even low tumor expression of HER3 may be 
indicative of pathway activation and consequently sensitivity to HER3 blocking agents. 
 Duligotuzumab (MEHD7945A) is a novel humanized phage-derived, dual-action 
antibody that blocks ligand binding to EGFR and HER3, with either antigen-binding fragment 
(Fab). When bound to these receptors, duligotuzumab blocks ligand binding (Kd huHER3 = 0.39 
nM; Kd hu EGFR = 1.9 nM), resulting in inhibition of ligand-driven signaling from EGFR/EGFR, 
EGFR/HER2, EGFR/HER3, and HER2/HER3 dimer pairs. As an IgG1 antibody, duligotuzumab 
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is also able to bind to Fc receptors and has demonstrated antibody-dependent cell-mediated 
cytotoxicity (ADCC) in in vitro models (18). In vivo, duligotuzumab shows activity in CRC KRAS 
wild-type xenograft models equal or superior to cetuximab, no effect in KRAS mutated models, 
and is additive in combination with chemotherapy (19). In CRC cell lines, standard 
chemotherapy may modulate the HER3/NRG network. These properties provided the rationale 
for investigating duligotuzumab for the treatment of patients with mCRC. 
 
Methods 
Study design 
 This open-label, randomized Phase II study enrolled patients with KRAS exon 2 wild-
type mCRC who progressed on/after oxaliplatin-containing chemotherapy. The primary 
objectives of this study were to 1) evaluate the efficacy of duligotuzumab + FOLFIRI vs. 
cetuximab + FOLFIRI in KRAS wild-type mCRC patients, and 2) evaluate the efficacy of 
duligotuzumab + FOLFIRI vs. cetuximab + FOLFIRI in KRAS wild-type mCRC patients whose 
tumors express low levels of HER3. The secondary objectives included evaluating the safety 
and tolerability of duligotuzumab vs. cetuximab in combination with FOLFIRI in KRAS exon 2 
wild-type mCRC patients, assess the effect of concomitant FOLFIRI on the pharmacokinetics 
(PK) of duligotuzumab and vice versa, and evaluate the incidence and impact of anti-
duligotuzumab antibodies.  
 Eligible patients were randomized in a 1:1 ratio and received duligotuzumab at a fixed 
dose of 1100 mg IV every 2 weeks (q2w) (Arm A). Patients in Arm B received cetuximab 
administered according to the prescribing label, with a loading dose of 400 mg/m2 IV on Day 1 
of Cycle 1, followed by weekly doses of 250 mg/m2 IV (2 x per cycle). No dose reductions were 
allowed for duligotuzumab and for cetuximab were limited to reductions for rash in accordance 
to its prescribing information. FOLFIRI chemotherapy was administered q2w (every cycle) 
starting on Day 1 of Cycle 1. FOLFIRI consisted of irinotecan (180 mg/m2), 5-FU (bolus and 46 
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hour infusional doses of 400 mg/m2 and 2400 mg/m2, respectively), and leucovorin (racemic, 
400 mg/m2 or L-isomer form, 200 mg/m2). Recommendations for chemotherapy dose reductions 
were in accordance to standard clinical practice. Dosing continued until progression or 
intolerable toxicity. An early per-protocol interim safety analysis occurred after an initial 6 and 
then 20 patients in each treatment arm received 2 cycles of treatment. 
 
Patients 
 Eligible patients age ≥ 18 years with histologically or cytologically confirmed 
adenocarcinoma of the colon and/or rectum, KRAS exon 2 wild-type status based on local 
assessment (EGFR expression status was not required for enrollment) and progressive disease 
on or after a first-line oxaliplatin-containing chemotherapy regimen for mCRC were enrolled into 
the study. Eastern Cooperative Oncology group (ECOG) performance status of 0-1, adequate 
hematologic and end organ function, and evaluable or measurable disease per modified 
RECIST v1.1 was required. Main exclusion criteria included prior treatment with irinotecan, 
HER-targeted agents, dihydropyrimidine dehydrogenase deficiency or current severe 
uncontrolled systemic disease. 
 The protocol was approved by Institutional Review Boards prior to patient recruitment 
and was conducted in accordance with International Conference on Harmonization E6 
Guidelines for Good Clinical Practice. Written informed consent was obtained for all patients 
prior to performing study-related procedures in accordance with federal and institutional 
guidelines.  
 
Safety assessments 
 Safety assessments consisted of recording protocol-defined adverse events (AEs) and 
serious AEs (SAEs); measurement of protocol specified hematology, clinical chemistry, and 
urinalysis variables; measurement of protocol specified vital signs; and other tests deemed 
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critical to the safety evaluation of the study drug(s). Safety was assessed by the incidence, 
nature, severity and relatedness of AEs, which were graded for severity according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0. All patients 
who received ≥ 1 dose of study treatment were included in the safety evaluation. Protocol-
defined Adverse Events of Special Interest included grade ≥ 3 events associated with infusion 
related reactions (defined as AEs occurring within 24 hours of infusion and attributed to 
treatment), grade ≥ 3 rash, grade ≥ 3 diarrhea, and grade ≥ 2 GI hemorrhage. 
 
Pharmacokinetic assessments 
  Serum samples for PK analysis were collected on Day 1 of each cycle. PK parameters 
were derived from non-compartmental analysis (Phoenix WinNonlin version 6.2) from the 
plasma concentration-time profile of duligotuzumab. A validated ELISA with a lower limit of 
quantitation of 150 ng/mL was used to measure the concentration of duligotuzumab in serum 
samples. All study samples were analyzed at Genentech. Plasma concentrations of 5-FU, 
irinotecan, and SN-38 were measured using validated liquid chromatography tandem mass 
spectrometry methods. Serum samples were assayed for the presence ATAs to duligotuzumab 
using a validated bridging ELISA. 
 
Activity outcomes 
 Per protocol, the primary efficacy outcome measure for this study was PFS in all patients 
with KRAS exon 2 wild-type mCRC and later restricted to RAS wild-type mCRC, and among 
patients whose tumors expressed low levels of HER3. PFS was defined as the time from study 
treatment initiation to the first occurrence of disease progression was determined by 
investigator review of tumor assessments with use of the modified RECIST v1.1, or death, 
whichever occurred first. Objective response by investigator assessment, duration of response, 
and overall survival were secondary efficacy outcome measures. Objective response was 
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defined as a complete or partial response according to modified RECIST v1.1; confirmed ≥ 4 
weeks after the initial response. Duration of objective response was defined as the time from 
first occurrence of a documented objective response until the time of relapse or death from any 
cause. OS was defined as the time from study treatment initiation to death from any cause. 
Time to treatment failure was defined as time from randomization to discontinuation of 
treatment for any reason, including disease progression, treatment toxicity, and death. 
 
Biomarker assessments 
 Tumor samples were mandatory and biomarker expression analysis focused on ERBB3 
and its ligand NRG1, as well as on EGFR and its ligands AREG and EREG, by qRT-PCR. IHC 
was used to determine protein expression and localization of HER3. Pre-cut tissue sections 
were stained for HER3 for analysis by IHC using the Ventana BenchMark® XT staining platform 
(Ventana Medical Systems, Inc., Tucson, AZ). Hematoxylin and eosin previously stained slides 
or images were reviewed to assess tissue quality and presence of tumor. IHC was performed in 
the TDx CAP/CLIA laboratory of VMSI using assays developed and validated in the 
Translational Diagnostics Laboratories of VMSI. Immunostaining was assessed by a board-
certified pathologist. 
 qRT-PCR was assessed using the fluidigm platform using an allele-specific PCR 
mutation panel that detects mutations in KRAS and NRAS in exon 2 (G12 and G13), exon 3 
(Q61), and exon 4 (K117 and A146) as previously described (20). 
 
Statistical methods 
 This Phase II trial was designed to make a preliminary comparison of the safety and 
efficacy of FOLFIRI + duligotuzumab versus FOLFIRI + cetuximab in patients with KRAS wild-
type mCRC and in those patients with low HER3 levels in their tumors. In particular, it was 
designed to obtain informative estimates of the PFS hazard ratios in the overall patient 
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population and the HER3-low patient population to enable further decision making. This trial is 
hypothesis generating and was not intended to detect the minimal clinically meaningful 
benefit. 
 
Results 
Patient characteristics 
 A total of 68 patients were enrolled in the duligotuzumab + FOLFIRI arm (78% RAS wild 
type), and 66 in the cetuximab + FOLFIRI arm (68% RAS wild type), from 22 Oct 2012 to 24 
December 2013 at 43 sites. The last patient’s final visit was completed on 26 November 2014; 
this date serving as the clinical data cutoff for the analyses. The baseline characteristics of the 
patient population are shown in Table 1 and were well balanced between treatment arms with 
the exception of a slight imbalance in sex, ECOG PS, RAS wt and PIK3CA mutation status. Of 
134 randomized patients, 98 were RAS exon 2/3 wild-type (n=53 in the duligotuzumab arm); 
BRAF and PIK3CA mutations were present in 15% and 12% of all patients enrolled. Sixty-five 
percent of patients were triple wild-type (RAS, BRAF, and PIK3CA). Most patients (77%) had 
progressed on first-line oxaliplatin within 6 months.  
 
Safety and tolerability  
 There were 67 and 63 patients in the duligotuzumab and cetuximab arms, respectively, 
who were evaluable for safety (Table 2). The most common AEs of any grade were rash (84%), 
diarrhea (79%), fatigue (62%), and nausea (50%). There were fewer rash events of any grade in 
the duligotuzumab arm but more diarrhea.  
 The incidence of grade ≥ 3 AEs was similar between arms (All AEs: 85% and 89%; 
related AEs 46% and 60%); overall, neutropenia (23%) was the most common AE of grade ≥ 3 
intensity, regardless of attribution. The frequency of SAEs was higher in the cetuximab arm 
(56% vs. 48% for duligotuzumab). AEs of special interest included grade ≥ 3 diarrhea that was 
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higher in the duligotuzumab arm (18%) compared to the cetuximab arm (14%), and grade ≥ 3 
infusion-related reactions (8% vs. 2%) and grade ≥ 3 rash (22% vs. 8%) were higher in the 
cetuximab arm. 
 AEs that led to a fatal outcome were reported in 3 patients on the duligotuzumab + 
FOLFIRI arm (pneumonia, respiratory failure, and one unknown cause of death), and 2 patients 
on the cetuximab arm (Campylobacter infection and lung infection). 
 SAEs occurred in 54% and 56% of patients on duligotuzumab vs. cetuximab arm. The 
SAEs regardless of attribution, occurring in ≥ 5% of patients were pyrexia (7%), diarrhea and 
pulmonary embolism (5% each). 
Treatment discontinuation of mAbs due to AEs was comparable in the duligotuzumab 
(14%) and cetuximab (16%) arms. However, cumulative dose intensity of FOLFIRI 
chemotherapy components was lower on the duligotuzumab vs. cetuximab arm (irinotecan: 66 
[24–100] vs. 75 [32–100]; 5-FU infusion 67 [24–99] vs. 74 [32–107]). In the duligotuzumab arm, 
select gastrointestinal (GI) toxicities (diarrhea, mucosal inflammation, and stomatitis) occurring 
at relatively high frequency led to disproportionately more frequent dose changes for irinotecan 
and 5-FU. For example, 52% of the stomatitis events occurring in the duligotuzumab arm led to 
chemotherapy dose modifications, while in the cetuximab arm, 8% of stomatitis events led to 
chemotherapy modifications. Furthermore, AEs leading to chemotherapy dose modifications, as 
a whole, occurred earlier in the duligotuzumab arm compared to the cetuximab arm. The 
median time of onset to first AEs for which irinotecan or 5-FU was modified (dose reduced, drug 
interrupted, or drug withdrawn) was 22 days in the duligotuzumab arm vs. 35 days in the 
cetuximab arm, of safety-evaluable patients. 
 
Pharmacokinetic analysis 
 In the duligotuzumab arm, mean peak and trough (± SD) serum concentrations of 
duligotuzumab were 299 μg/mL (± 66.3) and 39.5 μg/mL (± 43.7), respectively, in Cycle 1, and 
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the trough serum concentration was 76.0 (± 42.6) g/mL in Cycle 9 (Cycle 10, Day 1 [predose]). 
The data were comparable with previously reported serum duligotuzumab concentration data 
(equivalent dose of 14 mg/kg q2w IV) in the Phase I study (21). 
 There was no apparent effect of 5-FU and irinotecan co-administration on duligotuzumab 
PK. From an assessment of mean observed serum duligotuzumab trough concentration (69.4 
g/mL) from Cycle 3 (Cycle 4, Day 1 [predose]) onwards, there appeared to be minimal 
accumulation of duligotuzumab during the treatment period.  
 There was no evidence of trends in PFS or OS with duligotuzumab exposure, based on 
exposure-response analyses; indicating that dose was close or at the top of exposure-response 
curve. 
 The baseline prevalence of anti-therapeutic antibodies (ATAs) was 0% in the overall 
study population (0/70 patients). None of the 59 post-baseline evaluable patients treated with 
duligotuzumab had positive ATA results.  
 
Clinical activity 
 Efficacy results (Table 3A) show no benefit of duligotuzumab + FOLFIRI compared to 
cetuximab + FOLFIRI in RAS wild-type patients. Patients in the duligotuzumab arm did not show 
improved PFS by investigator assessment (Figure 1). In the RAS wild-type subgroup, median 
PFS was 7.3 vs. 5.7 months for duligotuzumab vs. cetuximab (stratified HR 1.21, 90% CI 0.81-
1.81). In HER3-low RAS wild-type randomized patients (based on the median ERBB3 qRT-PCR 
expression; [n=54]), the HR for PFS was 1.34 (90% CI, 0.80–2.25).  
  OS data were immature with 45% of OS events having occurred on the duligotuzumab 
and 49% on the cetuximab arm at the time to data cutoff (HR 1.00, 90% CI 0.61-1.66). Median 
OS was 14.0 months for duligotuzumab, and 13.1 months for cetuximab. Time to treatment 
failure was longer in the cetuximab arm compared to duligotuzumab. 
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 The objective response rate (ORR) was numerically lower in duligotuzumab-receiving 
patients (19%) compared to cetuximab (33%), (OR 0.47, 90% CI 0.21-1.01). Best overall 
response rates in the duligotuzumab arm consisted of 12 (23%) PR, as compared to 2 (4%) CR 
and 19 (42%) PR in the cetuximab arm. The waterfall plot for best CT response in Figure 2A 
shows the corresponding degree of tumor shrinkage in cetuximab vs. the duligotuzumab arm. 
Overall time on study treatment was lower on duligotuzumab vs. cetuximab (Figure 3).  
 
Biomarker analysis 
 By qRT-PCR, ERBB3 expression was in the range of 0.75-9.96 relative expression units 
(2^-dCT), and membranous staining of HER3 protein measured by IHC was observed with H-
scores ranging from 100-245. Neither HER3 protein levels nor relative gene expression based 
on RNA (ERBB3) showed a relationship with tumor shrinkage (Figure 2A) or PFS (Figure 2B). 
While no nuclear staining was observed, there was evidence for cytoplasmic staining. 
Comprehensive H-scores including both membranous and cytoplasmic staining patterns did not 
show benefit based on tumor response. 
 HER3 and EGFR ligand expression was also evaluated. NRG1 expression was in the 
range of 0.008-17.53 relative expression units (2^-dCT) in biopsy specimens but also failed to 
discriminate for response based on tumor shrinkage (22). Similarly, there was no clear 
relationship between AREG and EREG and best CT response or degree of tumor shrinkage. 
However, AREG and EREG, which were significantly correlated, showed a trend towards 
benefit in the cetuximab arm. EGFR levels showed no difference (22).  
 Evaluation of KRAS mutation status showed that 3.7% of samples exhibited mutations at 
codons 12 and 13 (exon 2, possibly undetected at screening), 0% with mutations at codon 61 in 
exon 3, and 117 (0.9%) and 146 (2.8%) in exon 4. Mutations in NRAS were detected at codons 
12 and 13 (1.9%) in exon 2, and 61 (1.9%) in exon 3; no mutations were detected in exon 4 at 
codons 117 and 146. Additionally, mutations in BRAF were observed in 15% of patients at 
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codon 600 (exon 15), but not in exon 11. Both NRAS and BRAF mutations were balanced 
between treatment arms. The majority of patients harboring mutations in KRAS exon 2 or 4, or 
BRAF, did not respond to either treatment arm (Table 3B), however, limited responses were 
observed in patients with mutations in NRAS (3 PRs, 2 cetuximab, 1 duligotuzumab arm). 
 
Discussion 
 HER3 is thought to have a functional role in CRC tumorigenesis (23). Although normal 
colonic tissue has little to no HER3 expression, HER3 is expressed in a significant proportion of 
colorectal tumors (24-29). Indeed, CRC tumors express high levels of NRG1and several EGFR 
ligands, suggesting that these tumors use both the EGFR and HER3 pathways to sustain 
proliferation (22).  
   
 Given the limited sample size no definitive conclusions can be drawn with respect to 
efficacy, however, a large clinical benefit was excluded. Furthermore, HER3 protein or gene 
expression levels did not select for benefit with duligotuzumab, nor did NRG1 or AREG 
expression. The mean peak and trough serum concentrations of duligotuzumab in the 
duligotuzumab + FOLFIRI arm were comparable to those previously reported (equivalent dose 
of 14 mg/kg q2w IV) in the Phase I study (21), indicating that there was no apparent effect of 5-
FU and irinotecan co-administration on the duligotuzumab PK. 
 Duligotuzumab in combination with FOLFIRI has an acceptable safety profile. The 
combination of duligotuzumab was overall well-tolerated with no unexpected safety findings. 
The overall incidence of AEs, SAEs, deaths, and withdrawal from the study due to AEs, dose 
modification/interruption due to AEs was comparable between the duligotuzumab and 
cetuximab arms. In the duligotuzumab arm there was less rash consistent with the Phase I 
study (21) and IRRs, however, more frequent all grades selected GI toxicities including diarrhea. 
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  A number of factors could have contributed to lower ORR in the duligotuzumab arm. For 
one, select GI toxicities (diarrhea, mucosal inflammation, and stomatitis) occurred at relatively 
high frequency and led to disproportionately more frequent and earlier dose changes for 
irinotecan and 5-FU. The more frequent occurrences of diarrhea and mucosal inflammation 
were associated with shorter duration and reduced dose intensity of the chemo backbone. The 
5-FU bolus was preferentially reduced to the lowest dose intensity in an attempt to counter 
these AEs. In addition, no severe imbalances were seen in overall incidence of grade 3-5 AEs, 
and the overall percentage of patients in whom irinotecan or 5-FU was modified due to a grade 
3–5 AE was similar between the arms. Therefore, it was mainly, and often multiple, grade 1–2 
AEs accounting for the disproportionally more frequent irinotecan and 5-FU dose modifications 
in the duligotuzumab arm.  
 The role of HER3 appears limited in the mCRC EGFR inhibitor naïve setting since there 
was no additional benefit of inhibiting HER3 in addition to EGFR. Expression of HER3 
measured by RNA or protein did not correlate with response suggesting a minor role for HER3 
in this disease. Conversely, the EGFR ligands AREG and EREG did show a trend towards 
improved survival in the cetuximab arm consistent with published data demonstrating stratified 
responses to antibody-based EGFR inhibitors (30). In the context of chemotherapy, it is difficult 
to discriminate specific differences between the two regimens but these data may suggest more 
potent EGFR clinical inhibitory activity by cetuximab (Kd = 0.2 nM, 31). The affinity of 
duligotuzumab is almost 1 log higher for HER3 than for EGFR (Kd huHER3 = 0.39 nM; Kd 
huEGFR = 1.9 nM; 32), which may in part explain the lack of additional benefit of duligotuzumab 
compared to cetuximab in this setting. Abrogation of dual HER3/EGFR signaling may explain 
the higher incidence of diarrhea and mucosal inflammation in the duligotuzumab arm, which has 
been seen with other HER3 inhibitors, and the lower affinity for EGFR could translate in a lower 
EGFR-signaling down regulation that may be the cause of the lower frequency of cutaneous 
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toxicities observed in the duligotuzumab-containing arm given the binding affinity of each 
compound.  
 Whether dual EGFR/HER3 inhibition could restore sensitivity once tumors have failed 
initial EGFR inhibition is something that we cannot rule out due to the design of this study. 
Receptor expression based on HER3 protein and gene expression analysis did not select for 
benefit with duligotuzumab. Similarly, the expression of the ligands, NRG1 and AREG also do 
not select for benefit. Unlike SCCHN, no relationship between NRG1 and EGFR ligands was 
noted (33-34). 
 In light of this and another randomized Phase 2 study in SCCHN showing no benefit for 
the dual inhibition of EGFR and HER3 over EGFR alone, neither in all randomized patients nor 
in biomarker selected subsets, we conclude that the role of dual HER3/HER1 inhibition remains 
not well understood in patients not previously treated with EGFR inhibitors. Further development 
of duligotuzumab has been stopped. 
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Tables 
 
Table 1.  
 
 
Duligotuzumab + 
FOLFIRI 
Cetuximab +  
FOLFIRI 
All Patients 
 
All 
(n=68) 
RAS WT 
(n=53, 
78%) 
All  
(n=66) 
RAS WT 
(n=45, 68%) 
All  
(N=134) 
RAS WT 
(N=98) 
Age (years), 
median (range) 
61 (21–85) 62 (21–85) 62 (26–82) 65 (39–82) 62 (21–85) 63 (21–85) 
Sex (male) 36 (53%) 27 (51%) 46 (70%) 34 (76%) 82 (61%) 61 (62%) 
Race (white) 60 (88%) 46 (87%) 59 (89%) 42 (93%) 119 (89%) 88 (90%) 
ECOG PS (0) 30 (45%) 24 (45%) 39 (62%) 25 (57%) 69 (53%) 49 (51%) 
BRAF mutation a 8 (12%) 8 (15%) 8 (12%) 8 (18%) 16 (12%) 16 (16%) 
PIK3CA mutation a 11 (20%) 9 (17%) 6 (12%) 4 (9%) 17 (16%) 13 (13%) 
Triple WT (RAS, 
BRAF and 
PIK3CA) a 
36 (64%) 36 (68%) 33 (65%) 33 (73%) 69 (65%) 69 (70%) 
Received prior 
bevacizumab 
32 (47%) 23 (44%) 31 (48%) 18 (40%) 63 (47%) 41 (42%) 
Time to PD on 
first-line 
oxaliplatin-based 
chemo (≤ 6 
months) 
53 (78%) 38 (72%) 50 (76%) 34 (76%) 103 (77%) 72 (74%) 
Primary tumor 
location 
     Left colon 
     Right colon 
     Rectum 
     Unknown 
 
 
22 (42%) 
12 (23%) 
19 (36%) 
0 
 
- 
- 
- 
- 
 
 
18 (40%) 
11 (24%) 
14 (31%) 
2 (4%) 
 
- 
- 
- 
- 
 
 
40 (41%) 
23 (24%) 
33 (34%) 
2 (2%) 
 
- 
- 
- 
- 
WT = wild-type; ECOG = Eastern Cooperative Oncology Group; PD = progressive disease. 
a The denominator for the all-randomized population is the number of patients with mutation 
data. 
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Table 2.  
 
MedDRA Preferred Term 
Duligotuzumab + 
FOLFIRI  
(n=67) 
Cetuximab +  
FOLFIRI 
(n=63) 
 
Any Grade ≥ Grade 3 Any Grade ≥ Grade 3 
All 67 (100%) 57 (85%) 63 (100%) 56 (89%) 
Rash and related terms a 53 (79%) 5 (8%) 56 (89%) 14 (22%) 
Diarrhea 61 (91%) 12 (18%) 42 (67%) 9 (14%) 
Fatigue 43 (64%) 6 (9%) 37 (59%) 10 (16%) 
Nausea 33 (49%) 3 (5%) 32 (50%) 2 (3%) 
Mucosal inflammation 26 (38%) 7 (10%) 23 (37%) 3 (5%) 
Stomatitis 21 (31%) 6 (9%) 26 (41%) 4 (6%) 
Alopecia 18 (27%) - 22 (35%) 1 (2%) 
Neutropenia 18 (27%) 14 (21%) 21 (33%) 16 (25%) 
Paronychia 21 (31%) 2 (3%) 18 (29%) 1 (2%) 
Hypokalemia 25 (37%) 4 (6%) 13 (21%) 4 (6%) 
Abdominal pain 13 (19%) 1 (2%) 22 (35%) 4 (6%) 
Decreased appetite 16 (24%) 2 (3%) 14 (22%) 2 (3%) 
Dry skin 17 (25%) - 13 (21%) - 
Infusion-related reaction b 13 (19%) 1 (2%) 17 (27%) 5 (8%) 
Vomiting 17 (25%) 4 (6%) 12 (19%) 3 (5%) 
Hand-foot syndrome 13 (19%) 1 (2%) 13 (21%) 2 (3%) 
a Rash and related MedDRA terms = rash dermatitis acneiform, rash maculo-papular, acne, 
dermatitis, rash macular, rash erythematous, rash pruritic, dermatitis atopic, dermatitis bullous, 
dermatitis exfoliative, rash generalized, rash papular, and rash pustular. 
b Any AE occurring during infusion or within 24 hours and suspected to be caused by 
duligotuzumab or cetuximab. 
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Table 3.  
A.  
 
B. 
 
 
PFS = progression-free survival; OS = overall survival; ORR: objective response rate (note that 
not all responses were confirmed)]; CI=confidence interval; NE=not estimated, WT = wild-type. 
a Stratified hazard ratio. 
All randomized RAS WT 
patients 
Duligotuzumab + 
FOLFIRI 
(n=53) 
Cetuximab + 
FOLFIRI 
(n=45) 
Hazard Ratioa or 
Odds Ratio (90% CI) 
PFS events 
Median PFS, mo (90% CI) 
41 (77%) 
7.3 (5.3, 8.1) 
35 (78%) 
5.7 (5.5, 7.7) 
1.21 (0.81, 1.81) 
OS events 
Median OS, mo (90% CI) 
24 (45%) 
14.0 (12.0, NE) 
22 (49%) 
13.1 (10.2, NE) 
1.00 (0.61, 1.66) 
ORR, % (90% CI) 
     Complete response 
     Partial response 
     Stable disease 
     Progressive disease 
     Missing/unevaluable 
10 (19%; 11, 29) 
- 
12 (23%) 
27 (51%) 
8 (15%) 
6 (11%) 
15 (33%; 22, 46) 
2 (4%) 
19 (42%) 
19 (42%) 
4 (9%) 
1 (2%) 
0.47 (0.21, 1.01) 
All randomized KRAS exon 
2 WT patients 
Duligotuzumab + 
FOLFIRI 
(n=68) 
Cetuximab + 
FOLFIRI 
(n=66) 
Hazard Ratioa 
or Odds Ratio 
(90% CI) 
PFS events 
Median PFS, mo (90% CI) 
54 (79%) 
5.4 (3.8, 7.5) 
50 (76%) 
5.6 (5.3, 7.5) 
1.30 (0.93, 
1.82) 
OS events 
Median OS, mo (90% CI) 
34 (50%) 
14.0 (11.0, 20.3) 
33 (50%) 
12.4 (10.2, NE) 
0.97 (0.64, 
1.46) 
ORR, % (90% CI) 
     Complete response 
     Partial response 
     Stable disease 
     Progressive disease 
     Missing/unevaluable 
11 (16%; 10, 24) 
-  
15 (22%) 
34 (50%) 
9 (13%) 
10 (15%) 
21 (32%; 22,  42) 
2 (3%) 
25 (38%) 
27 (41%) 
6 (9%) 
6 (9%) 
0.41 (0.21, 
0.83) 
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Table legends 
 
Table 1. Patient baseline and disease characteristics.  
 
Table 2. All AEs regardless of attribution in ≥ 20% of patients. 
 
Table 3. Summary outcomes in (A) all randomized RAS WT patients and (B) all randomized 
KRAS exon 2 WT patients.  
 
 
Figure legends 
 
Figure 1. Progression-free survival and number of patients at risk by duligotuzumab and 
cetuximab treatment arms. 
 
Figure 2. (A) Best response in duligotuzumab and cetuximab treatment arms in all randomized 
patients with RAS wildtype tumors with corresponding HER expression by membrane IHC H-
score and ERBB3 qRT-PCR. (B) Progression-free survival by duligotuzumab or cetuximab arm 
by membranous H-score and ERBB3 qRT-PCR quartile.  
 
Figure 3. Time on study treatment for duligotuzumab and cetuximab treatment arms. 
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